A comparison of parameters of kits for 99mTc-radiopharmaceuticals for a cerebral perfusion diagnostics

Authors: Jiří Štěpán
Authors‘ workplace: Klinika nukleární medicíny FN Brno a LF MU Brno
Published in: NuklMed 2013;2:7-12
Category: Original Article


[99mTc]technetium-exametazime was the first neutral lipophilic technetium compound able to pass through the blood–brain barrier. [99mTc]technetium-bicisate is another such a complex used in a clinical practice. Both radiopharmaceuticals are prepared by labeling of cold kits of various manufacturers, which differ by their parameters compared in this work.

A comparison of kits parameters mentioned in summaries of product characteristics (SPC), a determination of a radiochemical purity (RCP), a medical consultation of an imaging capability.

Parameters of kits for [99mTc]technetium-exametazime: BRAIN-SPECT KIT, NEUROSCAN, STABILISED CERETEC, and [99mTc]technetium-bicisate: NEUROLITE are mentioned respectively: a volume of a preparation: 5 ml, 5 ml, 7 ml, 4 ml; a maximum activity: 2.22 GBq, 1 GBq, 1.11 GBq, 3.7 GBq; a possibility of a dilution: yes, yes, yes, no; a volume of a vial: 9 ml, 10 ml, 11 ml, 5 ml; a kit stability before and after the labelling: 1 y / 1 h, 1 y / 0.5 h, 1 y / 5 h, 1.5 y / 8 h; obtained RCP / a percentage content of a free pertechnetate: 87.8 ± 0.6 / 5.9 ± 1.4, 86.6 ± 2.8 / 4.0 ± 2.7, 91.6 ± 0.9 / 1.9 ± 0.4, 97.2 ± 0.7 / not determined; comparable imaging capabilities; similar approved indications.

Main [99mTc]-bicisate (NEUROLITE) advantages against [99mTc]-exametazime (other kits) are the best stability, even not reached by STABILISED CERETEC, and a use of an [99mTc]eluate without any special restrictions. Nevertheless it isn't suitable for a leucocyte labelling. Among kits for [99mTc]-exametazim STABILISED CERETEC is characterized by its longer stability and BRAIN-SPECT KIT by the highest activity. A use of kits with the long stability (NEUROLITE, STABILISED CERETEC) reaching the highest RCP is advantageous by reason of the highest relative bioavailability for a brain.

Key words:
[99mTc]technetium-exametazime, [99mTc]technetium-bicisate, d,l-hexamethylpropylene amine oxime (HMPAO), L,L-ethyl cysteinate dimer (ECD), radiochemical purity, free pertechnetate


1. Neirinckx RD. Evaluation of regional cerebral blood flow with 99mTc-d,l-HMPAO and SPECT. Neurosurg Rev 1987;10:181–184

2. Banerjee S, Samuel G, Kothari K et al. On the synthesis, isolation and radiochemical studies for the preparation of in-house kit for 99mTc-meso- and d,l-HMPAO: A few additional observations. Nucl Med Biol 1999;26:327–338

3. Walovitch RC, Cheesman EH, Maheu LJ, Hall KM. Studies of the retention mechanism of the brain perfusion imaging agent 99mTc-bicisate (99mTc-ECD). J Cereb Blood Flow Metab. 1994;14 Suppl 1:S4-11

4. IAEA (International Atomic Energy Agency). Technetium-99m Radiopharmaceuticals: Manufacture of Kits. Vienna, IAEA, 2008, 189 p, Technical reports series no. 466, ISBN 978–92–0–100408–6

5. Škop B. Mikro-verze AISLP - ČR [CD-ROM]. 2013.1 pro MS Windows. Praha, Bohuslav Škop, 1. ledna 2013, 1 CD-ROM

6. Ministerstvo zdravotnictví ČR. Český lékopis 2009, ČL 2009 – Doplněk 2010, ČL 2009 – Doplněk 2011, ČL 2009 – Doplněk 2012: elektronická verze na CD. Praha, Grada, 2012, 1 CD-ROM, ISBN 859-404-924-026-5

7. Hodgson E, ed. A textbook of modern toxikology - 3rd edition. Hoboken, New Jersey, John Wiley & Sons, Inc., 2004, 557 p, ISBN 0-471-26508-X

Nuclear medicine Radiodiagnostics Radiotherapy
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account